cg0070,pembrolizumab
merck,cg oncology,kissei
['cg0070', 'core 1', 'pembro', 'bladder']
live from #asco22: shares core 1, a phase 2, single-arm study of cg0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer unresponsive to bacillus calmette-guerin. 
The official account of Moffitt Cancer Center. Our mission: to contribute to the prevention and cure of cancer. For news and stories visit https://t.co/XaP6iv4q19.